van Megen Y J, Klaassen A B, Rodrigues de Miranda J F, van Ginneken C A, Wentges B T
Department of Otorhinolaryngology, University of Nijmegen, The Netherlands.
J Allergy Clin Immunol. 1991 Feb;87(2):530-40. doi: 10.1016/0091-6749(91)90012-d.
Nasal hyperreactivity in nasal allergy may be due to changes of the characteristics in adrenergic receptors. Radioligand receptor-binding studies with the antagonists, 3H-prazosin (alpha 1-adrenoceptor), 3H-rauwolscine (alpha 2-adrenoceptor), and 125I-(-)-Cyanopindolol (beta-adrenoceptor) were performed in homogenates of nasal mucosa of allergic and nonallergic (NA) patients to investigate this hypothesis. The heterogeneous NA group was subdivided into control individuals and patients with chronic sinusitis and vasomotor rhinitis. No significant differences in affinities or densities of alpha 1- and alpha 2-adrenoceptors could be demonstrated in allergic patients in comparison with NA and control individuals. The beta-adrenoceptor density was significantly reduced in allergic patients in comparison with that of control individuals. Neither changes in agonist binding or in the effect of Gpp(NH)p on the agonist binding to beta-adrenoceptors could be observed in allergic patients. The subtype selective antagonist, LK203-030, demonstrated the presence of a homogeneous population of beta 2-adrenoceptors in human nasal mucosa of both NA and allergic patients. In vitro, autoradiography demonstrated specific 125I-(-)-Cyanopindolol labeling of the epithelium in NA and allergic patients. In conclusion, no changes in characteristics of alpha 1- or alpha 2-adrenoceptors in the nasal mucosa could be demonstrated in nasal allergy. However, a decreased number of beta-adrenoceptors may reflect a beta-adrenergic abnormality in nasal allergy.
鼻过敏中的鼻高反应性可能归因于肾上腺素能受体特性的改变。为了研究这一假说，我们使用拮抗剂3H-哌唑嗪（α1-肾上腺素能受体）、3H-萝芙辛（α2-肾上腺素能受体）和125I-（-）-氰基吲哚洛尔（β-肾上腺素能受体）对变应性和非变应性（NA）患者的鼻黏膜匀浆进行放射性配体受体结合研究。异质性NA组又细分为对照组个体以及患有慢性鼻窦炎和血管运动性鼻炎的患者。与NA组和对照组个体相比，变应性患者的α1-和α2-肾上腺素能受体的亲和力或密度没有显著差异。与对照组个体相比，变应性患者的β-肾上腺素能受体密度显著降低。在变应性患者中，未观察到激动剂结合的变化或Gpp（NH）p对激动剂与β-肾上腺素能受体结合的影响。亚型选择性拮抗剂LK203-030表明，在NA患者和变应性患者的人鼻黏膜中均存在均一的β2-肾上腺素能受体群体。在体外，放射自显影显示在NA患者和变应性患者中，上皮细胞有特异性的125I-（-）-氰基吲哚洛尔标记。总之，在鼻过敏中未发现鼻黏膜α1-或α2-肾上腺素能受体特性的改变。然而，β-肾上腺素能受体数量的减少可能反映了鼻过敏中的β-肾上腺素能异常。
